Lorvotuzumab

Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab) ) is a humanized monoclonal antibody that binds CD56 (NCAM1) . Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].

Product Specifications

CAS Number

[339306-30-8]

Product Name Alternative

Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lorvotuzumab.html

Purity

99.77

Solubility

10 mM in DMSO

Smiles

[Lorvotuzumab]

Molecular Weight

(146.44 kDa)

References & Citations

[1]James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126 (24) :5303-5310.